- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT06796699
A Phase Ia/Ib Clinical Study of GH56 Capsules in Subjects With MTAP-Deleted Advanced Solid Tumors(G-MAP 101)
Um estudo clínico de fase IA/IB de braço único, de braço e um braço único, avaliando a segurança, tolerabilidade, farmacocinética, farmacodinâmica e eficácia preliminar de cápsulas de GH56 em indivíduos com tumores sólidos avançados com MTAP Delegados
This is a multicenter, single-arm, open-label, dose-escalation, dose-expansion study to evaluate the safety, tolerability, PK/PD, and preliminary anti-tumor activity of GH56 Capsule in subjects with advanced solid tumors who have failed or are intolerant to standard treatment, or have no standard therapy. The clinical trial will be carried out in two parts: phase Ia study (dose escalation study) and phase Ib (dose expansion study).The Part Ib dose expansion study includes adult cohort and adolescent cohort (12-17 years of age).
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Tipo de estudo
Inscrição (Estimado)
Estágio
- Fase 1
Contactos e Locais
Contato de estudo
- Nome: Bo Ning, Master
- Número de telefone: +86-0512-86861608
- E-mail: nibo@genhousebio.com
Locais de estudo
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, China, 100730
- Recrutamento
- Peking Union Medical College Hospital
-
Contato:
- Lin Zhao, Doctorate
- E-mail: zhaolin4412@pumch.cn
-
Investigador principal:
- Lin Zhao, Doctorate
-
Beijing, Beijing Municipality, China, 100021
- Recrutamento
- Cancer Hospital Chinese Academy of Medical Sciences
-
Contato:
- Ning Li, Doctorate
- Número de telefone: +86-010-87788495
- E-mail: lining@cicams.ac.cn
-
Investigador principal:
- Ning Li, Doctorate
-
Beijing, Beijing Municipality, China, 100044
- Recrutamento
- Peking University People's Hospital
-
Contato:
- Lu Xie, Doctorate
- E-mail: xielu@pkuph.edu.cn
-
Investigador principal:
- Lu Xie, Doctorate
-
Beijing, Beijing Municipality, China, 100070
- Ativo, não recrutando
- Beijing Tiantan Hospital,Capital Medical University
-
-
Fujian
-
Fuzhou, Fujian, China, 350014
- Recrutamento
- Fujian Cancer Hospital
-
Contato:
- Yunjian Huang, Doctorate
- E-mail: 13805099580@126.com
-
Investigador principal:
- Yunjian Huang, Doctorate
-
Xiamen, Fujian, China, 361003
- Recrutamento
- The First Affiliated Hospital of Xiamen University
-
Contato:
- Jianbo Chen, Doctorate
- E-mail: 274439002@qq.com
-
Investigador principal:
- Jianbo Chen, Doctorate
-
-
Gansu
-
Lanzhou, Gansu, China, 730000
- Recrutamento
- Gansu Provincial Hospital
-
Contato:
- Bo Li, Doctorate
- E-mail: doctorli2022@163.com
-
Investigador principal:
- Bo Li, Doctorate
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510060
- Recrutamento
- Sun Yat-sen University Cancer Center
-
Contato:
- Xing Zhang, Doctorate
-
Investigador principal:
- Xing Zhang, Doctorate
-
Guangzhou, Guangdong, China, 510515
- Recrutamento
- Nanfang Hospital
-
Contato:
- Laiyu Liu, Doctorate
- E-mail: liulaiyu@126.com
-
Investigador principal:
- Laiyu Liu, Doctorate
-
-
Guangxi
-
Nanning, Guangxi, China, 530200
- Recrutamento
- Guangxi Medical University Cancer Hospital
-
Contato:
- Yongkui Lu, Doctorate
- E-mail: luyongkui616@126.com
-
Investigador principal:
- Yongkui Lu, Doctorate
-
-
Guizhou
-
Guiyang, Guizhou, China, 550081
- Recrutamento
- The Second People's Hospital of Guiyang
-
Contato:
- Zhuang Kang, Doctorate
- E-mail: kzhaoren1984@163.com
-
Investigador principal:
- Zhuang Kang, Doctorate
-
-
Henan
-
Zhengzhou, Henan, China, 450008
- Recrutamento
- Henan Cancer Hospital
-
Contato:
- Qiming Wang, Doctorate
- E-mail: qimingwang1006@126.com
-
Investigador principal:
- Qiming Wang, Doctorate
-
-
Hubei
-
Wuhan, Hubei, China, 430022
- Recrutamento
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
-
Contato:
- Jing Chen, Doctorate
-
Investigador principal:
- Jing Chen, Doctorate
-
-
Hunan
-
Changsha, Hunan, China, 410008
- Recrutamento
- Xiangya Hospital of Central South University
-
Contato:
- Huaping Yang, Doctorate
- E-mail: lyhuaping@aliyun.com
-
Investigador principal:
- Huaping Yang, Doctorate
-
-
Jiangsu
-
Nanjing, Jiangsu, China, 210008
- Recrutamento
- Nanjing Drum Tower Hospital
-
Contato:
- Rutian Li, Doctorate
- E-mail: li_rutian@163.com
-
Investigador principal:
- Rutian Li, Doctorate
-
-
Jilin
-
Changchun, Jilin, China, 130033
- Ativo, não recrutando
- China-Japan Union Hospital of Jilin University
-
-
Shandong
-
Binzhou, Shandong, China, 256603
- Recrutamento
- Shandong Medical and Pharmaceutical University Hospital
-
Contato:
- Fangling Ning, Doctorate
- E-mail: ningfangling@126.com
-
Investigador principal:
- Fangling Ning, Doctorate
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, China, 200233
- Recrutamento
- Shanghai Sixth People's Hospital
-
Contato:
- Haiyan Hu, Doctorate
- Número de telefone: +86-021-64369181
- E-mail: xuri1104@163.com
-
Investigador principal:
- Haiyan Hu, Doctorate
-
Shanghai, Shanghai Municipality, China, 201200
- Recrutamento
- Shanghai GoBroad Caner Hospital China Pharmaceutical University
-
Contato:
- Yayi He, Doctorate
- Número de telefone: +86-021-60571205
- E-mail: doctorjael@qq.com
-
Investigador principal:
- Yayi He, Doctorate
-
-
Shanxi
-
Taiyuan, Shanxi, China, 30009
- Recrutamento
- Shanxi Provincial Cancer Hospital
-
Contato:
- Wei Guo, Doctorate
- Número de telefone: +86-0351-4881611
- E-mail: guowei812@126.com
-
Investigador principal:
- Wei Guo, Doctorate
-
-
Sichuan
-
Yibin, Sichuan, China, 644000
- Recrutamento
- The Second People's Hospital of Yibin
-
Contato:
- Kaijian Lei, Doctorate
- E-mail: lkj600@163.com
-
Investigador principal:
- Kaijian Lei, Doctorate
-
-
Uygur Autonomous Region
-
Ürümqi, Uygur Autonomous Region, China, 830054
- Recrutamento
- The First Teaching Hospital of Xinjiang Medical University
-
Contato:
- Shaya Mahati, Doctorate
- E-mail: 398022226@qq.com
-
Investigador principal:
- Ji Chen, Doctorate
-
Investigador principal:
- Shaya Mahati, Doctorate
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310022
- Recrutamento
- Zhejiang Cancer Hospital
-
Contato:
- Zhengbo Song, Doctorate
- E-mail: songzb@zjcc.org.cn
-
Investigador principal:
- Zhengbo Song, Doctorate
-
Hangzhou, Zhejiang, China, 310009
- Recrutamento
- The Second Affiliated Hospital Zhejiang University School of Medicine
-
Contato:
- Binghao Li, Doctorate
- E-mail: libinghaohz@163.com
-
Investigador principal:
- Binghao Li, Doctorate
-
Taizhou, Zhejiang, China, 317000
- Recrutamento
- Taizhou Hospital of Zhejiang Province
-
Contato:
- Dongqing Lv, Doctorate
- E-mail: lvdq855@126.com
-
Investigador principal:
- Dongqing Lv, Doctorate
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Willing to participate in the clinical trial, understand and sign the informed consent, and comply with the study visits and procedures.
- Male and female patients who are ≥12 years of age at consent .
- Histologically or cytologically confirmed advanced and/or metastatic malignancies with progression on / intolerance to standard treatment or lack of effective standard treatment.
- Evidence of MTAP loss or homozygous MTAP/CDKN2A deletion in tumor tissue.
- At least one measurable lesion as per RECIST v1.1 criteria.
- Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1.
- Survival expectations ≥ 12 weeks.
- Adequate organ function
- Has a negative serum pregnancy test result at screening and is able to comply with contraceptive-barrier requirements.
Exclusion Criteria:
- Subject has not recovered from a prior surgical procedure or has undergone any major surgery within 4 weeks prior to the first dose.
- Has received any anti-tumor agents within 28 days without delayed toxicity for the treatment of advanced tumors prior to the first administration of GH56 Capsule
- Has symptomatic or active progressive central nervous system (CNS) metastases such as molluscum contagiosum metastases.
- Subjects who have difficulty in swallowing and have a history of gastrointestinal surgery or other relevant medical disorders that may interfere with the absorption of GH56.
- Subjects had a malignant tumor other than the current tumor within 5 years prior to the first administration of GH56 Capsule, except for localized cancers that have been apparently cured or without disease progression or recurrence for at least 5 consecutive years.
- Uncontrolled or significant cardiovascular disease
- Subjects with documented positive virology status of hepatitis, as confirmed by Screening hepatitis B virus (HBV) and hepatitis C virus (HCV) tests, Human Immunodeficiency Virus (HIV).
- Conditions that the investigator considers inappropriate for participation in this clinical trial.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: GH56 Capsule Group
Dose-escalation cohorts and dose-expansion cohorts receiving varying doses of GH56. |
GH56 capsule for oral administration at specified doses on scheduled days. |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
1. Determination of Maximum Tolerated Dose (MTD) , RDEs of GH56.
Prazo: Approximately 3 years
|
MTD is the highest dose of a treatment that does not cause unacceptable side effects. RDEs stand for Recommended Dose for Expansion. |
Approximately 3 years
|
|
Characterize the Safety of GH56
Prazo: Approximately 3 years
|
Number of participants with treatment-emergent adverse events and serious AEs. |
Approximately 3 years
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Objective Response Rate (ORR)
Prazo: Approximately 3 years
|
Based on assessment of radiographic imaging per RECIST version 1.1 |
Approximately 3 years
|
|
Disease Control Rate (DCR)
Prazo: Approximately 3 years
|
Based on assessment of radiographic imaging per RECIST version 1.1 |
Approximately 3 years
|
|
Duration of Response (DOR)
Prazo: Approximately 3 years
|
Based on assessment of radiographic imaging per RECIST version 1.1 |
Approximately 3 years
|
|
Progression-Free Survival (PFS)
Prazo: Approximately 3 years
|
Based on assessment of radiographic imaging per RECIST version 1.1 |
Approximately 3 years
|
|
Cmax
Prazo: Approximately 3 years
|
The maximum or "peak" concentration of GH56 observed after administration |
Approximately 3 years
|
|
Tmax
Prazo: Approximately 3 years
|
The time to peak concentration of GH56 |
Approximately 3 years
|
|
T1/2
Prazo: Approximately 3 years
|
Half-life of GH56 |
Approximately 3 years
|
|
PD of GH56
Prazo: Approximately 3 years
|
Change of sDMA protein expression in tumor tissues |
Approximately 3 years
|
Colaboradores e Investigadores
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Outros números de identificação do estudo
- GH56C101
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .